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Fas (CD95), a member of the tumor necrosis factor-receptor superfamily, has been studied 
extensively as a death-inducing receptor in the immune system. However, Fas is also widely 
expressed in a number of other tissues, including in neurons. Here, we report that defects in 
the Fas/Fas ligand system unexpectedly render mice highly susceptible to neural degeneration 
in a model of Parkinson’s disease. We found that Fas-deficient lymphoproliferative mice develop 
a dramatic phenotype resembling clinical Parkinson’s disease, characterized by extensive 
nigrostriatal degeneration accompanied by tremor, hypokinesia, and loss of motor coordination, 
when treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at a 
dose that causes no neural degeneration or behavioral impairment in WT mice. Mice with 
generalized lymphoproliferative disease, which express a mutated Fas ligand, display an 
intermediate phenotype between that of lymphoproliferative
 
 
 
and WT mice. Moreover, Fas 
engagement directly protects neuronal cells from MPTP/1-methyl-4-phenylpyridinium ion 
toxicity in vitro. Our data show that decreased Fas expression renders dopaminergic neurons 
highly susceptible to degeneration in response to a Parkinson-causing neurotoxin. These 
findings constitute the first evidence for a neuroprotective role for Fas in vivo.
 
Fas is commonly categorized as a death receptor
because of its well-defined role in apoptosis (1).
It is expressed throughout the central nervous
system, including in glia and neurons (2), and
induces neuronal apoptosis under certain condi-
tions, such as in models of stroke and amyo-
trophic lateral sclerosis (3–5). In this report, we
investigated the role of Fas signaling in a mouse
model of Parkinson’s disease (PD). PD is a
chronic and debilitating neurodegenerative dis-
order, characterized by degeneration of the mid-
brain dopaminergic neurons of the substantia
nigra pars compacta (SN), resulting in the hall-
mark symptoms of the disease, namely tremor,
bradykinesia, rigidity, and postural instability.
The etiology of PD is unknown, and in up to
95% of cases there is no identified genetic link-
age (6). Environmental factors, such as neuro-
toxic pesticides, have been implicated in disease
pathogenesis. Exposure to the dopaminergic
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) provides a well-established model
of PD in rodents and primates and has been
shown to cause PD in humans (6). MPTP crosses
the blood–brain barrier where it is metabolized
to its active form, the 1-methyl-4-phenylpyri-
dinium ion (MPP
 
 
 
), which is concentrated
selectively in dopaminergic neurons by the dopa-
mine transporter, resulting in dopaminergic neu-
ronal death.
In PD patients, membrane-bound Fas and
Fas ligand (FasL) expression are reduced in the
SN (7). Concomitantly, soluble Fas, which
acts as a decoy receptor and blocks the binding
of FasL to Fas, is elevated in PD (8, 9). Thus,
Fas signaling in PD patients may be diminished
by reduced cell surface Fas expression and by
the presence of soluble Fas. Apoptosis is be-
lieved to be a factor in the neurodegeneration
of PD (10), but in vitro models indicate that
caspase-8, the upstream caspase activated during
Fas-mediated apoptosis, is not involved, sug-
gesting that Fas may not be the principal death
effector in PD neurodegeneration (11).
 
The online version of this article contains supplemental material.
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We used mice bearing mutations in the Fas/FasL system to
determine directly the role of Fas signaling in the MPTP model
of PD. We demonstrate here that reduced Fas expression dra-
matically increases neuronal susceptibility to MPTP toxicity in
vivo, strongly supporting a neuroprotective role for Fas.
 
RESULTS AND DISCUSSION
Fas deficiency results in markedly increased susceptibility 
to MPTP-induced dopaminergic neuron degeneration
 
We compared the MPTP susceptibility of WT C57BL/6
(B6), Fas-deficient lymphoproliferative (
 
lpr
 
), and FasL-
mutated generalized lymphoproliferative (
 
gld)
 
 mice that share
the B6 genetic background. 
 
Lpr
 
 mice express low to absent
cell surface Fas because of the insertion of a transposable ele-
ment within a Fas intron (12). 
 
Gld
 
 mice have a point muta-
tion in the extracellular domain of FasL that decreases the af-
finity of the Fas/FasL interaction, resulting in reduced
signaling through Fas (13, 14). We treated mice with a sub-
acute toxicity regimen of MPTP consisting of an injection of
25 mg/kg/d for 5 consecutive d and quantified tyrosine hy-
droxylase positive (TH
 
 
 
) neurons as a marker for dopami-
nergic neurons in the midbrain (SN and ventral tegmental
area, VTA) 4 d after the final injection of MPTP. Consistent
with previous findings (15), WT mice treated with this sub-
acute regimen of MPTP exhibited only a marginal, nonsig-
nificant loss of midbrain dopaminergic neurons at this time
point (Fig. 1, A–C). In contrast, we observed a dramatic loss
of dopaminergic neurons in Fas-deficient mice. We found
that the SN and VTA of MPTP-treated 
 
lpr
 
 mice showed a
58% (P 
 
 
 
 0.001) and 40% (P 
 
 
 
 0.05) loss of dopaminergic
neurons, respectively, compared with saline-treated 
 
lpr
 
 mice.
MPTP-treated 
 
gld
 
 mice lost 26% (P 
 
 
 
 0.05
 
)
 
 of the dopami-
nergic neurons in the SN compared with saline-treated 
 
gld
 
mice (Fig. 1, A–C). The pretreatment number of TH
 
 
 
 neu-
rons was not significantly different in 
 
lpr
 
, 
 
gld
 
, and WT mid-
brains (Fig. 1, B–C). The depletion of neuron cell bodies in
the SN of MPTP-treated 
 
lpr
 
 mice was confirmed in cresyl
violet–stained sections (unpublished data). We also observed
a striking decrease in dopaminergic innervation to the stria-
tum in MPTP-treated 
 
lpr
 
 mice and to a lesser extent in 
 
gld
 
mice (Fig. 1 D). In fact, the loss of terminals in the caudate
putamen of the striatum and the sparing of the olfactory tu-
bercle and nucleus accumbens in MPTP-treated 
 
lpr
 
 mice re-
semble the pattern of terminal loss seen in the striatum of PD
patients. The increased susceptibility of 
 
lpr
 
 mice to MPTP
occurs despite lower levels of MPP
 
 
 
 accumulation in the
striatum than WT B6 mice, as determined by HPLC 4 h af-
ter the third dose of MPTP (B6: 3.29 
 
 
 
 0.15 
 
 
 
g/g tissue;
 
lpr
 
: 2.29 
 
 
 
 0.12 
 
 
 
g/g tissue; 
 
gld
 
: 2.13 
 
 
 
 0.37 
 
 
 
g/g tissue).
Increased neurodegeneration in the presence of decreased
levels of bioavailable MPP
 
 
 
 further emphasizes the enhanced
sensitivity to neurodegeneration in the absence of Fas. Thus,
Fas-deficient 
 
lpr
 
 mice treated with MPTP display a dramatic
degeneration of the nigrostriatal system. 
 
Gld
 
 mice, which
have a partial Fas-signaling deficit (14), demonstrate an inter-
mediate degree of neuronal loss.
 
Fas deficiency results in tremor, hypokinesia, and decreased 
motor coordination after MPTP treatment
 
WT mice did not exhibit significant spontaneous behavioral
changes during or after the MPTP treatment course. In sharp
contrast, we found that Fas-deficient 
 
lpr
 
 mice displayed
marked hypokinesia (Fig. 2 A) and developed a tremor after
the second to third dose of MPTP (Videos 1–3, available at
http://www.jem.org/cgi/content/full/jem.20050163/DC1).
Over four independent experiments, 78% of the 
 
lpr
 
 mice
(
 
n
 
 
 
 
 
 32) became immobile during the first 4 d after the
initiation of MPTP treatment, although they gradually re-
covered spontaneous mobility (Fig. 2 B). WT mice main-
tained normal activity levels throughout the treatment
course (Fig. 2, A and B), and 
 
gld
 
 mice displayed a behavioral
Figure 1. Massive loss of dopaminergic neurons and striatal pro-
jections in MPTP-treated Fas-deficient mice. (A) TH-stained sections 
through the midbrain (SN and VTA) in MPTP- or saline-treated WT, lpr, and 
gld mice. (B, C) The number of TH  neurons in the SN (B) and VTA (C) was 
determined by unbiased stereology (n   4; *, P   0.05; ***, P   0.001; 
error bars show SE). (D) TH-stained sections through the striatum in saline- 
or MPTP-treated WT, lpr, and gld mice. No loss of staining is observed in 
WT striata, but extensive depletion of SN projections to the caudate putamen 
with relative sparing of the nucleus accumbens and olfactory tubercle is 
seen in lpr mice. 
JEM VOL. 202, September 5, 2005
 
577
 
BRIEF DEFINITIVE REPORT
 
phenotype more closely resembling that of WT mice, corre-
lating with their less severe neuronal loss (Fig. 2 A).
Over the 5 d of MPTP treatments, the 
 
lpr
 
 mice were too
impaired for assessment of coordination. 3 d after the final
MPTP injection, we found no impairment in WT mice,
consistent with previous work (15). However, we observed
that 
 
lpr
 
 mice had impaired coordination by Rotarod testing,
achieving only 39% (P 
 
 
 
 0.05) of the score of their WT
counterparts (Fig. 2 C). 
 
Gld
 
 mice seemed to be slightly im-
paired, but this decrease did not reach statistical significance.
Thus, Fas-deficient mice became severely hypokinetic, de-
veloped tremor, and displayed decreased coordination after
exposure to MPTP at a dose that causes no spontaneous be-
havioral deficits in WT mice.
These results suggest that Fas provides a neuroprotective
signal that is missing in 
 
lpr
 
 mice and is reduced in 
 
gld
 
 mice.
This putative Fas-induced neuroprotective signal is probably
ligand dependent, because 
 
gld
 
 mice, like 
 
lpr
 
 mice, displayed
increased susceptibility to neuronal loss after MPTP adminis-
tration, although degeneration was less extensive in 
 
gld
 
 mice
than in 
 
lpr
 
 mice. The residual signal transmitted through Fas
in 
 
gld
 
 mice (14) might explain the less severe degenerative
and behavioral phenotype seen in 
 
gld
 
 mice as compared with
 
lpr
 
 mice.
 
Fas engagement is protective against MPTP/MPP
 
 
 
 
neurotoxicity in vitro, and this neuroprotection is 
independent of caspase-8 activation
 
To determine whether Fas engagement is directly protective
against MPTP toxicity in dopaminergic neurons, we treated
cultured midbrain neurons with a FasL construct to induce
Fas signaling, followed by exposure to MPTP. Treatment
with FasL protected primary TH
 
 
 
 neurons from MPTP tox-
icity (Fig. 3 A). We repeated this experiment using the Fas-
positive neuroblastoma cell line SH-SY5Y to determine
whether Fas-induced neuroprotection operated indepen-
dently of glia. We found that administration of FasL signifi-
cantly reduced MPP
 
 
 
 toxicity (Fig. 3 B). Fas-mediated pro-
tection did not occur in a Fas-negative subline of SH-SY5Y
cells (Fig. 3 B). To determine whether the neuroprotective
effect of Fas required caspase-8 activation, we used a specific
cell permeant caspase-8 inhibitor, IETD-fmk, which effec-
tively protects Jurkat T cells from FasL-induced apoptosis
(Fig. 3 C). Unlike Fas-mediated apoptosis, Fas-mediated
neuroprotection was not blocked by IETD-fmk (Fig. 3 D).
Thus, Fas engagement protected dopaminergic neurons
from MPTP/MPP
 
 
 
 toxicity even in the absence of glia and
independently of caspase-8 activation.
 
Fas-mediated neuroprotection in vivo is independent 
of the Fas death domain
 
Our in vitro data suggested that Fas-mediated neuroprotec-
tion may be independent of the Fas death domain (DD), be-
cause the DD serves to anchor and activate caspase-8 via the
adaptor protein Fas-associated DD. We tested this hypothesis
in two strains of mice bearing disruptions in their Fas DD.
Mice bearing an engineered disruption of the Fas DD (16)
commonly are referred to as “Fas null,” because Fas-induced
death is abolished in these mice. However, the mice express
a truncated Fas molecule lacking exon 9, which encodes
most of the DD, but retain the remainder of the intracellular
Fas domains as well as Fas expression at the cell surface, un-
like 
 
lpr
 
 mice, which express no detectable Fas by flow cy-
tometry (Fig. 4 A). These Fas exon 9 KO mice are resistant
to MPTP (Fig. 4 A and reference 17), in contrast to the dra-
matic susceptibility of 
 
lpr
 
 mice, as shown by striatal dopa-
mine and dopamine metabolite levels. These mice show no
significant differences in MPP
 
 
 
 levels (Exon 9 KO: 3.48 
 
 
 
0.34 
 
 
 
g/g; B6: 3.29 
 
 
 
 0.15 
 
 
 
g/g). We propose that this dif-
ference in susceptibility between 
 
lpr
 
 and exon 9 KO mice is
based on Fas expression levels (Fig. 4 A), with Fas expression
being neuroprotective.
An analogous, naturally occurring point mutation,
 
lpr.cg
 
, causes local unfolding of the DD and likewise abol-
ishes Fas-induced apoptosis, although 
 
lpr.cg
 
 mice express
normal levels of cell surface Fas and can mediate nonapop-
Figure 2. Lpr mice become profoundly hypokinetic after exposure to 
MPTP. (A) Total activity and rearing are shown for WT, lpr, and gld mice (same 
mice as in Fig. 1). Scores were generated as the ratio of pretreatment to post-
treatment activity for each mouse. Activity was measured 20 h after the 
second injection of MPTP to avoid the acute effects of the toxin. **, P   0.01. 
(B) Pooled behavioral analysis over four experiments is shown (B6: n   18; lpr: 
n   32). ***, P   0.001. (C) Rotarod scores were calculated as the ratio of per-
formance of MPTP-treated to saline-treated mice 3 d after the final injection 
of MPTP. *, P   0.05. 
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totic signaling (18). The lpr.cg mutation is available only on
the CBA background; therefore, lpr.cg mice cannot be
compared directly with lpr, Fas exon 9 KO, and gld mice,
all of which are on the B6 background. Therefore, we
compared MPTP susceptibility of lpr.cg mice with that of
their WT CBA counterparts. We found no significant dif-
ference in TH  neuron loss in the SN of lpr.cg versus WT
CBA mice (Fig. 4 B); in fact, we observed a statistically sig-
nificant protection in the VTA of lpr.cg compared with
CBA mice (Fig. 4 B). Behaviorally, both Fas exon 9 KO
and lpr.cg mice were resistant to MPTP administration (ref-
erence 17 and Fig. 4 B, respectively). Together, these data
indicate that a functional DD is not required for Fas-medi-
ated neuroprotection. The observation that Fas exon 9 KO
(17) and lpr.cg mice are slightly more resistant to MPTP
than are WT mice suggests that Fas neuroprotective signal-
ing in the absence of Fas apoptotic signaling may confer
Figure 3. Fas-induced neuroprotection is independent of caspase-8 
activation. (A) Primary dopaminergic neurons were treated as shown 
with FasL and/or 50  M MPTP. Untreated cells are defined as having 
100% viability. (B) Fas-positive and -negative SH-SY5Y cells (as assessed 
by flow cytometry) were treated with FasL (black line) or PBS (gray line) 30 
min before MPP  exposure. 100% viability represents untreated SH-SY5Y 
cells. (C) Jurkat cells were killed by FasL, and this cell death was blocked by 
the caspase-8 inhibitor IETD-fmk. (D) SH-SY5Y cells were treated with 
IETD-fmk 1 h before addition of FasL and/or 800  g/ml MPP  to the 
culture. Error bars show SE.
Figure 4. Fas-mediated neuroprotection in vivo is independent of 
the Fas DD. (A) Exon 9 KO mice have a deleted DD and are no more sus-
ceptible to MPTP than are WT mice. Lpr mice (MPTP-susceptible) do not 
express detectable Fas, whereas WT and exon 9 KO mice express Fas as 
determined by flow cytometry (Fas expression, solid line; background 
staining, dotted lines). MPTP-treated lpr mice show reduced striatal dopamine, 
dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA), as 
determined by HPLC, compared with B6 and exon 9 KO mice. Serotonin 
levels were included as a control and were not affected by MPTP. (B) Lpr.cg 
mice have a disrupted DD and are no more susceptible to MPTP than WT 
CBA mice, as shown by TH  neuron counts (saline-treated, black bars; 
MPTP, gray bars; n   3) and behavior (CBA, black bars; lpr.cg, gray bars; 
n   4–6). Methodology was as described in Figs. 1 and 2.JEM VOL. 202, September 5, 2005 579
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additional protection from MPTP toxicity. The abnormal
immune system, which is characteristic of mice lacking
Fas-induced death, is present in Fas exon 9 KO, gld, lpr.cg,
and lpr mice, demonstrating that the immune abnormality
in itself does not alter neuronal susceptibility to MPTP
toxicity, because lpr.cg and exon 9 KO mice are protected,
whereas lpr mice become dramatically more susceptible.
Fas is up-regulated in the midbrain in response to
MPTP (17) and, indeed, is up-regulated by multiple types
of injuries or stress to the central nervous system (2). We
propose that Fas up-regulation may represent an adaptive
response to stress, resulting in neuroprotection when the
cell is salvageable and neuronal apoptosis when the damage
is too severe for the cell to be rescued. We have recently
shown that Fas engagement can mediate neurite outgrowth
via activation of the extracellular-signal regulated kinase
(ERK) pathway, independent of caspase-8 (18). Fas en-
gagement similarly can activate ERK in neural stem cells
(19). Furthermore, it has been demonstrated previously
that ERK phosphorylation can mediate a protective stress
response in neurons (20), and there is growing evidence
that neuroprotective kinase pathways, when disrupted, may
lead to genetically determined PD in humans (21). Thus,
Fas expressed by stressed neurons may provide protective
signals via protein kinase pathways that, when disrupted,
lead to increased susceptibility to PD.
PBLs from PD patients show decreased Fas up-regulation 
upon activation
Because of the extreme susceptibility to toxin-induced PD
demonstrated by mice with reduced Fas expression, we in-
vestigated Fas expression in patients diagnosed as having id-
iopathic PD. We obtained blood samples from patients who
had PD and from controls who did not have PD as a simple
and minimally invasive means to measure Fas expression.
We found that baseline Fas expression in PBLs from patients
who had PD did not differ from that in control subjects who
did not have PD. However, when we stimulated the periph-
eral blood T cells (PBTs) with mitogen to induce Fas up-
regulation, we found a highly significant deficit (P   0.001)
in the ability of PBTs from PD patients to up-regulate Fas
(Fig. 5). Thus, patients who have PD show an impairment of
Fas up-regulation, at least in PBTs.
Although it is possible that the medication prescribed for
PD may influence Fas regulation, two of the patients in-
cluded in our study were not taking any medication, and
both of these individuals displayed very low levels of Fas up-
regulation, similar to levels in treated patients who had PD.
Furthermore, there was no correlation between level of Fas
up-regulation and disease duration in our patients. Thus, it is
possible that decreased ability to up-regulate Fas was a pre-
existing condition in these patients. If this impairment in Fas
up-regulation in T cells correlates with defective up-regula-
tion of Fas in other tissues upon cellular stress, this impair-
ment may confer predisposition to PD. Although the clinical
data are in accordance with the results from our mouse
study, it will be important to validate the clinical findings in
a larger patient population.
Our studies demonstrate for the first time that a reduc-
tion in Fas expression or signaling dramatically increases
neuronal susceptibility to neurodegeneration in vivo,
strongly supporting a neuroprotective role for Fas, at least in
some contexts. We propose that the lack of Fas in lpr mice
and the decreased Fas signaling in gld mice is responsible for
the increased neuronal death caused by the lack of a Fas-
dependent neuroprotective signal. The striking level of
dopaminergic neuron degeneration in the midbrain of
MPTP-treated lpr mice, together with their profound be-
havioral phenotype, may provide a new model for PD re-
search in which potential therapeutics and neuroprotective
strategies can be tested. Moreover, individuals with an im-
paired ability to up-regulate Fas expression may be at in-
creased risk of developing PD after exposure to environ-
mental neurotoxins.
MATERIALS AND METHODS
Mice and MPTP treatment. We used 8–10-wk-old female B6 (Charles
River Laboratories), lpr, gld, Fas exon 9 KO (“Fas null”), CBA, and lpr.cg
mice (Jackson ImmunoResearch Laboratories). We administered five sub-
Figure 5. Fas up-regulation is decreased in patients who have PD. 
(A) Representative flow cytometry histograms show that cell surface Fas 
expression is up-regulated by activation on PBTs from control subjects but 
not on PBTs from patients who have PD. Histograms show background 
staining (dotted lines), Fas expression on unstimulated T cells (black lines) 
and Fas expression on activated T cells (thick gray lines). (B) Fas up-regulation 
on T cells, calculated as the difference in mean Fas fluorescence between 
unstimulated and activated T cells (as shown in 5 A), is shown for control 
subjects and patients who have PD (P   0.001). Filled circles represent the 
two PD patients not taking medication. Proliferation (% blast, 12.0   2.5 
for controls; 13.7   4.9 for PD patients) and viability (97   1 live cells for 
controls, 95   2 live cells for PD patients) were equivalent in the T cells 
from control and PD patients.DEFECTIVE FAS EXPRESSION IN PARKINSON’S DISEASE | Landau et al. 580
cutaneous injections of 25 mg/kg MPTP (Sigma-Aldrich) or saline, once
per day for 5 consecutive d. Mice were used according to the protocols ap-
proved by McGill University Animal Care Committee.
Behavioral analysis. We performed automated activity monitoring
(AM1053 system, Cambridge Neurotechnology Ltd.) over 5-min periods.
We assessed Rotarod (IITC Life Science) performance as the average of
three trials of 1 min each at 20 revolutions/min. Statistical analysis was by
analysis of variance and Tukey test.
Brain preparation, immunohistochemistry, and stereology. We
perfused mice, cut 50- m coronal brain sections through the striatum and
midbrain using a freezing sledge microtome (Leica), and performed immu-
nohistochemistry with anti-TH antibody (1:2,000, Pel-Freez Biologicals)
on every third serial section (22). A second series was processed using 0.1%
cresyl violet as a Nissl stain. We obtained unbiased stereology estimates of
midbrain dopaminergic neurons using StereoInvestigator software (Micro-
BrightField) as described previously (22).
Primary cultures. We prepared and treated P2–P5 midbrain cells from
B6 mice with MPTP as described (23). FasL construct (400 ng/ml, Sigma-
Aldrich) was administered where indicated 30 min before MPTP. After 7 d,
TH  cells were stained with IgG-PE Zenon kit (Molecular Probes) bound
to monoclonal mouse anti-TH antibody (Sigma-Aldrich).
Neuroprotection assay. We plated 2   104 Fas-positive SH-SY5Y neu-
roblastoma cells per well in phenol-red–free DMEM in 96-well plates. We
pretreated the cells with FasL construct (100 ng/ml), added MPP  at the in-
dicated concentrations 30 min later, then incubated the cells for 3 d at
37 C/5% CO2. We assayed cell viability using WST-1 reagent (Roche Di-
agnostics) according to the manufacturer’s instructions. As a control, the
same procedure was performed on Fas-negative SH-SY5Y cells. IETD-fmk
(BD Biosciences) was used where indicated and was tested by incubating
104 Jurkat cells/well at 37 C for 1 h with IETD-fmk to which FasL (100
ng/ml) was added for 2.5 h. WST-1 was used to assay viability.
HPLC. HPLC was performed as described (24) with modifications (see
supplemental Materials and methods, available at http://www.jem.org/cgi/
content/full/jem.20050163/DC1). Monoamines were detected with an
ESA system with 5011 analytical cells, and a Higgins Analytical HAISIL 100
C18 column (5  m, 150   4.6 mm). MPP  levels were measured using a
Beckman 32 Karat System with a diode array detector (295 nm) on a Gem-
ini C18 RP 150   4.6 mm analytical column (Phenomenex, Inc.).
Patients. We recruited patients who had idiopathic PD from five consecu-
tive weekly Montreal Neurological Institute Movement Disorders Clinics.
Diagnosis of idiopathic PD was established according to the following crite-
ria: tremor, bradykinesia, and rigidity (two of three), asymmetric onset, re-
sponse to dopaminergic medication (in patients taking medication), and ab-
sence of the following signs suggesting another diagnosis: early dementia,
early falls or balance problems, severe autonomic dysfunction, and use of
neuroleptic medications (25, 26). Patients with concurrent inflammatory
diseases were excluded. Only men were included in this study, because we
were unable to recruit enough women for statistical significance. Age-
matched men with no history of PD or inflammatory disease were recruited
as controls (average ages: patients with PD, 65.78   6.94 yr; control sub-
jects, 68.43   15.41 yr). We obtained informed consent from all partici-
pants, and all experiments involving humans were approved by the Institu-
tional Review Board of McGill University.
Flow cytometry. We stimulated mouse lymph node cells overnight with
2.5 g/ml Concanavalin A (Sigma-Aldrich) in RPMI 1640/10% FCS and
then labeled the cells with PE-conjugated anti-mouse CD95 or PE-conju-
gated isotype-matched control antibodies (BD Biosciences). Human PBLs
were prepared by ficoll density centrifugation from 10 ml blood. PBLs were
divided into unstimulated cells and stimulated cells using Concanavalin A as
described earlier. Cells were labeled with FITC-conjugated anti-human
CD3 and PE-conjugated anti-human CD95 or PE-conjugated isotype-
matched control antibodies (BD Biosciences). Fas up-regulation was de-
fined as the change in mean PE fluorescence between the unstimulated and
stimulated populations gated on live CD3  cells.
Online supplemental material. Videos 1–3 show mice 20 h after the
second and third doses of MPTP. Mice and MPTP treatment were as de-
scribed in Materials and methods. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20050163/DC1.
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